Abstract
Our understanding of monoclonal, allergen-specific IgE antibodies has been hindered by the scarcity of circulating IgE-producing B cells, which are rare even in allergic individuals. The potential to isolate single B cells producing IgE antibodies and class switch these antibodies to IgG4 antibodies, like those that increase with allergen-specific immunotherapy, could be of great therapeutic value.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
